Immunophotonics is attending SIO Scientific Meeting in Savannah, Georgia. Our President, Robert Arch, PhD, and CIO & Co-Founder, Tomas Hode, PhD, will share updates on IP-001, an intratumoral immunotherapy designed to activate the patient’s immune system following ablation, with the goal of reducing recurrence risk while preserving the current standard of care.

If you are an interventional oncologist or practicing physician interested in therapies that improve tumor ablation outcomes while integrating seamlessly into the clinical workflow, we invite you to connect. Schedule time with us or stop by our Booth #513 to discuss clinical fit, mechanism of action, and ongoing progress.